Article Text

other Versions

Controversies in FH: A Commentary on the NICE Guideline for the Identification and Management of Familial Hypercholesterolemia
  1. R Minhas (rminhas{at}
  1. RAND Coroporation, United States
    1. S E Humprhries
    1. British Heart Foundation, United Kingdom
      1. N Qureshi
      1. Uttoxeter Road, Derby, DE22 3DT, United Kingdom
        1. Neil Haw
        1. University of Oxford, United Kingdom


          Introduction: Familial hypercholesterolemia (FH) is one of the most common monogenic inherited conditions in clinical practice and has a prevalence of about 1 in 500, similar to type 1 diabetes. In the UK over 85% of the estimated 120,000 people who are thought to be affected remain undiagnosed. The National Institute for Health and Clinical Excellence (NICE) has recently developed a clinical guideline for the identification and management of FH 1. This review summarises some of the key controversies appraised by the guideline development group (GDG) in its consideration of the evidence, including assessing the cost-effectiveness of alternative diagnostic and identification strategies and of different low density lipoprotein cholesterol (LDL-C) lowering treatments.

          Statistics from

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.